ArticleBMJ open2026

Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol.

Kai He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.